Stock Analysis

Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?

ENXTPA:ABVX
Source: Shutterstock

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. As with many other companies ABIVAX Société Anonyme (EPA:ABVX) makes use of debt. But the more important question is: how much risk is that debt creating?

When Is Debt Dangerous?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

See our latest analysis for ABIVAX Société Anonyme

How Much Debt Does ABIVAX Société Anonyme Carry?

As you can see below, at the end of December 2020, ABIVAX Société Anonyme had €34.0m of debt, up from €20.7m a year ago. Click the image for more detail. However, it also had €29.3m in cash, and so its net debt is €4.68m.

debt-equity-history-analysis
ENXTPA:ABVX Debt to Equity History June 7th 2021

How Healthy Is ABIVAX Société Anonyme's Balance Sheet?

We can see from the most recent balance sheet that ABIVAX Société Anonyme had liabilities of €24.9m falling due within a year, and liabilities of €28.5m due beyond that. Offsetting these obligations, it had cash of €29.3m as well as receivables valued at €2.77m due within 12 months. So it has liabilities totalling €21.3m more than its cash and near-term receivables, combined.

Since publicly traded ABIVAX Société Anonyme shares are worth a total of €400.6m, it seems unlikely that this level of liabilities would be a major threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. Carrying virtually no net debt, ABIVAX Société Anonyme has a very light debt load indeed. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if ABIVAX Société Anonyme can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

Given its lack of meaningful operating revenue, ABIVAX Société Anonyme shareholders no doubt hope it can fund itself until it has a profitable product.

Caveat Emptor

Over the last twelve months ABIVAX Société Anonyme produced an earnings before interest and tax (EBIT) loss. To be specific the EBIT loss came in at €40m. Considering that alongside the liabilities mentioned above does not give us much confidence that company should be using so much debt. So we think its balance sheet is a little strained, though not beyond repair. Another cause for caution is that is bled €31m in negative free cash flow over the last twelve months. So suffice it to say we consider the stock very risky. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. These risks can be hard to spot. Every company has them, and we've spotted 5 warning signs for ABIVAX Société Anonyme (of which 2 are concerning!) you should know about.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

If you’re looking to trade ABIVAX Société Anonyme, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About ENXTPA:ABVX

ABIVAX Société Anonyme

A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.

Flawless balance sheet with limited growth.